[S22] Goat Anti-4 HNE (4 Hydroxynonenal) AntiserumHNE40S-G1a
Specifically binds to 4-HNE modified proteins. Dilution for immunoblot and ELISA range: 1,000 to 20,000.
The antibody can be used for detection of of 4-HNE modification in plasma, lipoproteins, and other proteins, immunoassays, immunoblots, enzyme conjugation, or biotinylation.
|Storage:||Freeze-dried product should be stored refrigerated until opened. After opening, restore to suggested ml volume with distilled water. If it is not completely clear after standing for 1-2 hours at room temperature, centrifuge the product. It is stable for several weeks at 4°C as an undiluted liquid. Do not use for more than one day after dilution. For extended storage after reconstitution, we suggest aliquot to avoid repeated freezing and thawing; or the addition of an equal volume of glycerol to make a final glycerol concentration of 50%, followed by storage at -20°C. The concentration of protein and buffer salts will decrease to one-half of the original after the addition of glycerol.|
*These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.
Modifications on lysine residues, with formation of carboxylmethyl-lysine (CML), malondialdehyde (MDA) and hexitol-lysine are advanced glycation end-products (AGE), and the coupling with reactive aldehyde compounds, such as 4-hydroxynonenal (4-HNE) may appear from lipid oxidation (Guichardant et al., 1998). These modifications feature the oxidative byproducts which react with NH2 groups and form Schiff-base adducts (Mark et al., 1996). LDL treated with HNE or oxidatively modified by Cu++ or by cultured endothelial cells give rise to Michael addition-type HNE adducts that are recognized by HNE-specific antibodies.
Guichardant M, Taibi-Tronche P, Fay LB, Lagarde M. Covalent modifications of aminophospholipids by 4-hydroxynonenal. Free Radic Biol Med. 1998 Dec;25(9):1049-56.
Mark S. Bolgar, Chao-Yuh Yang, and Simon J. Gaskell, First Direct Evidence for Lipid/Protein Conjugation in Oxidized Human Low Density Lipoprotein (LDL), JBC, 271: 27999-28001 (1996).